SCHEMBL20903527

SCHEMBL20903527

c1ccc(C(=C(c2ccccc2)c2ccc(-c3cc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)cc(-c4nc5ccccc5s4)c3)cc2)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.50
▸ KDM4E B2RXH2 8/20 0.50
▸ SMN1; SMN2 Q16637 6/20 0.50
▸ MAPT P10636 6/20 0.50
▸ ALDH1A1 P00352 5/20 0.50
▸ NPC1 O15118 5/20 0.50
▸ NFKB1 P19838 4/20 0.50
▸ NFKB2 Q00653 4/20 0.50
▸ RELA Q04206 4/20 0.50
▸ LMNA P02545 3/20 0.50
▸ APP P05067 3/20 0.50
▸ MMP9 P14780 2/20 0.50
▸ MMP8 P22894 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ GLA P06280 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ MMP2 P08253 1/20 0.49
▸ MMP13 P45452 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20894815 0.91 RAB9A (0.52) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL27258689 0.88 APP (0.54) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL21319434 0.85 RAB9A (0.57) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL24331861 0.85 RAB9A (0.62) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL27049348 0.84 RAB9A (0.61) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL24332088 0.83 RAB9A (0.65) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL24331812 0.83 RAB9A (0.65) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL27049351 0.82 APP (0.60) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL9958225 0.82 RAB9A (0.56) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL24332163 0.82 RAB9A (0.67) RAB9AKDM4ESMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470398-B1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2022-05-04 — — EP disclosed
US-20200317704-A1 Organic Electronic Device Comprising an Organic Semiconductor Layer NOVALED GMBH (DE) 2020-10-08 — — US disclosed
WO-2019072932-A1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2019-04-18 — — WO disclosed
EP-3470398-A1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER Novaled GmbH (DE) 2019-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317704-A1 Organic Electronic Device Comprising an Organic Semiconductor Layer SELE, EPCAM, OR51E2 RAB9A 3011/4885KDM4E 163/4885SMN1; SMN2 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback